New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

What is your approach to post-kidney transplant erythrocytosis for an asymptomatic patient already on ACEi but with Hb consistently >18?

2
1 Answers

Mednet MemberInvited Expert
Hematology · Massachusetts General Hospital Cancer Center

My approach is to rule out non-transplant-associated causes of erythrocytosis (examples include obstructive sleep apnea, checking for renal artery stenosis, etc.). Once the diagnosis of post-kidney transplant erythrocytosis has been met, we typically use ACEi/ARB as you mention in the question. If t...

Would you consider octreotide as an adjunctive therapy for patients experiencing an acute life-threatening hemorrhage, outside of standard indications such as variceal or AVM bleeding?

2 Answers

Mednet MemberInvited Expert
Hospital Medicine · Emory University Hospital

In very selective scenarios, when the patient is experiencing an acute life-threatening bleeding while variceal or AVM bleeding remains on the differential, yes, I would consider octreotide as an adjunctive therapy, but only as a bridge to definitive diagnosis and treatment and not as a substitute f...

Would you consider weekly low-dose decitabine and weekly venetoclax (metronomic dosing) in frail patients with high-risk MDS?

2 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

I find the metronomic dosing regimen of decitabine + venetoclax in high-risk myeloid malignancies (particularly TP53-mutated malignancies) very intriguing but have used the regimen sparingly thus far in the absence of randomized data supporting its use.When thinking about higher-risk MDS, we have da...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you view epcoritamab + R² in an older or frail patient with follicular lymphoma who would otherwise be a candidate for additional treatment after progresion on first line therapy?

2 Answers

Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

Older and frail patients often derive less benefit from repeated chemotherapy as cumulative toxicity becomes increasingly important. ER2 offers the potential for a highly effective chemotherapy-free approach while maintaining an acceptable safety profile, but I think careful patient selection is ess...

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

3 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Northwestern University Feinberg School of Medicine

Currently, there are no standard criteria used to choose CAR-T over conventional stem cell transplant as destination therapy. However, there are many factors that often push us in one direction or the other. As we learn more about outcomes after CAR-T cell therapy, there are many factors we know are...

Would you treat patient with early stage unfavorable classic Hodgkin lymphoma with 6 cycles instead of 4 cycles of Nivo-AVD to avoid mediastinal radiation in young female?

1
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Brigham and Women's Hospital

I would tailor the number of cycles to the clearance of PET positivity. If one is considering stopping at 4 cycles, I would do a PET scan after 2 cycles and only stop at 4 if it was negative. If it is positive after 2 cycles, I would repeat the PET scan after 4 cycles. If it is still positive, an al...

What radiation doses and subsequent treatment monitoring would you recommend for multiple myeloma patients with multifocal bony lesions who decline chemotherapy?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

Systemic therapy is the cornerstone of treatment for multiple myeloma, and the vast majority of patients initiate an appropriate regimen upon diagnosis. Occasionally, patients will have very limited disease and will be referred to Radiation Oncology for consideration of local therapy to delay the ne...

In a pregnant patient with cyclic neutropenia who has ANC nadirs <500/µL but no history of significant infections or other neutropenia-related complications, would you initiate G-CSF during pregnancy?

1 Answers

Mednet MemberInvited Expert
Hematology · Georgetown University School of Medicine

Understand that I am not an expert, but no, I would not. As long as she is asymptomatic, I would manage expectantly. If an expert recommends otherwise, I would defer without question.

What therapy do you usually choose in patients with previously treated follicular lymphoma who experience early relapse (<2 years)?

6
6 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center

My approach to POD24 patients is to first ensure there is no evidence of transformed disease. According to a retrospective analysis led by @Dr. First Last at Memorial Sloan Kettering, as many as 40% of the POD24 patients have evidence of transformed disease if a biopsy is pursued. Clinical indicator...

How do you decide between anticoagulation and observation for an incidentally detected subsegmental pulmonary embolism in elderly patients with a history of gastrointestinal bleeding?

6
7 Answers

Mednet MemberInvited Expert
Pulmonology · Tufts Medical Center

We face this conundrum not infrequently because subsegmental emboli are subject to high inter-reader variability, and the accuracy of the finding in isolation is suspect (Batayneh et al., Blood 2023). I once mentioned this to a radiologist who reads CTAs and was told, tactfully, that I was full of i...